1. Medtech Insight

Quality Systems Issues Take Center Stage In Integra, Hologic Warning Letters

 
• By Elizabeth Orr

The US FDA has published warning letters to device firms Integra and Hologic. Both letters recount quality systems issues, with Integra’s centering on sterility while Hologic’s addresses a delay in noting safety signals from the company’s recalled BioZorb markers.

Red envelopes around a red exclamation point, with the exclamation point seen through a magnifying glass.
(MMD Creative/Shutterstock)

Compliance issues at Integra and Hologic facilities have caught the US Food and Drug Administration’s attention, with the agency publishing lengthy warning letters to both companies on 14 January.

The 18 December Hologic letter discusses the FDA’s findings during a late-summer 2024 inspection of the company’s Marlborough, Mass., headquarters. The facility makes BioZorb markers, which are currently...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medtech Insight

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.